• 1
    Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4: 489499.
  • 2
    Larrey D, Pageaux GP. Drug-induced acute liver failure. Eur J Gastroenterol Hepatol 2005; 17: 141143.
  • 3
    Jaeschke H, Bajt ML. Intracellular signaling mechanisms of acetaminophen-induced liver cell death. Toxicol Sci 2006; 89: 3141.
  • 4
    Gujral JS, Knight TR, Farhood A, Bajt ML, Jaeschke H. Mode of cell death after acetaminophen overdose in mice: apoptosis or oncotic necrosis? Toxicol Sci 2002; 67: 322328.
  • 5
    Kon K, Kim JS, Jaeschke H, Lemasters JJ. Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes. HEPATOLOGY 2004; 40: 11701179.
  • 6
    Jaeschke H. Role of inflammation in the mechanism of acetaminophen-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 2005; 1: 389397.
  • 7
    Blazka ME, Elwell MR, Holladay SD, Wilson RE, Luster MI. Histopathology of acetaminophen-induced liver changes: role of interleukin 1 alpha and tumor necrosis factor alpha. Toxicol Pathol 1996; 24: 181189.
  • 8
    Ishida Y, Kondo T, Ohshima T, Fujiwara H, Iwakura Y, Mukaida N. A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J 2002; 16: 12271236.
  • 9
    Gunawan BK, Liu ZX, Han D, Hanawa N, Gaarde WA, Kaplowitz N. c-Jun N terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 2006; 131: 165178.
  • 10
    Henderson NC, Pollock KJ, Frew J, Mackinnon AC, Flavell RA, Davis RJ, et al. Critical role of c-jun (NH2) terminal kinase in paracetamol-induced acute liver failure. Gut 2007; 56: 982990.
  • 11
    Latchoumycandane C, Goh CW, Ong MM, Boelsterli UA. Mitochondrial protection by the JNK inhibitor leflunomide rescues mice from acetaminophen-induced liver injury. HEPATOLOGY 2007; 45: 412421.
  • 12
    Bourdi M, Korrapati MC, Chakraborty M, Yee SB, Pohl LR. Protective role of c-Jun N-terminal kinase 2 in acetaminophen-induced liver injury. Biochem Biophys Res Commun 2008; 374: 610.
  • 13
    Hanawa N, Shinohara M, Saberi B, Gaarde WA, Han D, Kaplowitz N. Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. J Biol Chem 2008; 283: 1356513577.
  • 14
    Nakagawa H, Maeda S, Hikiba Y, Ohmae T, Shibata W, Yanai A, et al. Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology 2008; 135: 13111321.
  • 15
    Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem 1998; 273: 1992519928.
  • 16
    Prasanna SJ, Saha B, Nandi D. Involvement of oxidative and nitrosative stress in modulation of gene expression and functional responses by IFNgamma. Int Immunol 2007; 19: 867879.
  • 17
    Frezza C, Cipolat S, Scorrano L. Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts. Nat Protoc 2007; 2: 287295.
  • 18
    Owens CW, Belcher RV. A colorimetric micro-method for the determination of glutathione. Biochem J 1965; 94: 705711.
  • 19
    Cocco T, Di Paola M, Papa S, Lorusso M. Arachidonic acid interaction with the mitochondrial electron transport chain promotes reactive oxygen species generation. Free Rad Biol Med 1999; 27: 5159.
  • 20
    Nagase T, Kawata S, Tamura S, Matsuda Y, Inui Y, Yamasaki E, et al. Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells. Br J Cancer 1997; 76: 10011010.
  • 21
    Caponigro F, Casale M, Bryce J. Farnesyl transferase inhibitors in clinical development. Expert Opin Investig Drugs 2003; 12: 943954.
  • 22
    Delgado A, Casas J, Llebaria A, Abad JL, Fabrias G. Inhibitors of sphingolipid metabolism enzymes. Biochim Biophys Acta 2006; 1758: 19571977.
  • 23
    Kröger H, Dietrich A, Ohde M, Lange R, Ehrlich W, Kurpisz M. Protection from acetaminophen-induced liver damage by the synergistic action of low doses of the poly(ADP-ribose) polymerase-inhibitor nicotinamide and the antioxidant N-acetylcysteine or the amino acid L-methionine. Gen Pharmacol 1997; 28: 257263.
  • 24
    Tan SC, New LS, Chan EC. Prevention of acetaminophen (APAP)-induced hepatotoxicity by leflunomide via inhibition of APAP biotransformation to N-acetyl-p-benzoquinone imine. Toxicol Lett 2008; 180: 174181.
  • 25
    Degeorge KC, Degeorge BR Jr, Testa JS, Rothstein JL. Inhibition of oncogene-induced inflammatory chemokines using a farnesyltransferase inhibitor. J Inflamm (Lond) 2008; 5: 3.
  • 26
    James LP, Lamps LW, McCullough S, Hinson JA. Interleukin 6 and hepatocyte regeneration in acetaminophen toxicity in the mouse. Biochem Biophys Res Commun 2003; 309: 857863.
  • 27
    Grypioti AD, Theocharis SE, Demopoulos CA, Papadopoulou-Daifoti Z, Basayiannis AC, Mykoniatis MG. Effect of platelet-activating factor (PAF) receptor antagonist (BN52021) on acetaminophen-induced acute liver injury and regeneration in rats. Liver Int 2006; 26: 97105.
  • 28
    Yang R, Miki K, He X, Killeen ME, Fink MP. Prolonged treatment with N- acetylcystine delays liver recovery from acetaminophen hepatotoxicity. Crit Care 2009; 13: R55.
  • 29
    Richmond RE, DeAngelo AB, Daniel FB. Immunohistochemical detection of ras and myc oncogene expression in regenerating rat liver. Toxicol Lett 1992; 60: 119129.
  • 30
    da Silva Morais A, Saliez A, Leclercq I, Horsmans Y, Stärkel P. Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats. Clin Sci 2008; 114: 7383.
  • 31
    Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 1997; 275: 16491652.
  • 32
    Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, Hirai T et al. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 1999; 274: 79367940.
  • 33
    Xue X, Lai KT, Huang JF, Gu Y, Karlsson L, Fourie A. Anti-inflammatory activity in vitro and in vivo of the protein farnesyltransferase inhibitor tipifarnib. J Pharmacol Exp Ther 2006; 317: 5360.
  • 34
    Na HJ, Lee SJ, Kang YC, Cho YL, Nam WD, Kim PK, et al. Inhibition of farnesyltransferase prevents collagen-induced arthritis by down-regulation of inflammatory gene expression through suppression of p21(ras)-dependent NF-kappaB activation. J Immunol 2004; 173: 12761283.
  • 35
    Sugita M, Sugita H, Kaneki M. Farnesyltransferase inhibitor, manumycin a, prevents atherosclerosis development and reduces oxidative stress in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 13901395.
  • 36
    Sonoda K, Sakamoto T, Yoshikawa H, Ashizuka S, Ohshima Y, Kishihara K, et al. Inhibition of corneal inflammation by the topical use of Ras farnesyltransferase inhibitors: selective inhibition of macrophage localization. Invest Ophthalmol Vis Sci 1998; 39: 22452251.